Driving Innovation in Epigenetics: EpiCypher's Remarkable Achievements in 2024

EpiCypher, based in Durham, North Carolina, has declared 2024 a groundbreaking year, boasting seven peer-reviewed publications and over 550 product citations, underscoring the company's significant contribution to chromatin research and drug development. This impressive feat showcases EpiCypher's dedication to advancing genomic science through top-of-the-line technologies, assays, and services.

Dr. Michael-Christopher Keogh, EpiCypher's Chief Scientific Officer, expressed pride in the company’s productivity, stating, "The quality of research generated through our CUTANA™ CUT&RUN and CUT&Tag epigenomics assays and nucleosome substrates is remarkable. Our R&D efforts this year have been incredibly robust, and we eagerly anticipate new applications in collaboration with our partners as we move into 2025."

Pioneering Research Highlights

In 2024, EpiCypher collaborated with a myriad of scientists across various research disciplines, with contributions to 16 manuscripts, including seven publications and notable preprints. Key themes from this research demonstrate the cutting-edge advancements being made in epigenomics:

Development of Reader CUT&RUN technology to analyze co-occurring epigenomic features (collaboration with Catherine Musselman featured in *eLife*).

Investigation into nucleosome structure to enhance understanding of disease-relevant chromatin interactions (*Science Advances*).

Discoveries surrounding novel chromatin remodeling pathways that correlate with immunotherapy resistance, as discussed in *Cell*.

Innovative high-throughput nucleosome screening technologies that analyze histone ubiquitination PTMs in chromatin binding mechanisms, appearing in *Nucleic Acids Research*.

Reflections on the evolution of chromatin research, highlighting the impactful legacy of David Allis.

An upgraded, comprehensive CUT&RUN protocol that includes improved sample preparation guidelines and bioinformatics support.

Global Impact and Diverse Applications

EpiCypher's technologies have gained noteworthy traction worldwide in 2024, with product citations from countries including the United States, Canada, Germany, Australia, and China. The versatility of the CUTANA CUT&RUN and CUT&Tag systems has facilitated essential discoveries across a variety of applications, such as:

Identifying new drug targets derived from CRISPR screening studies.

Enhancing T cell immunotherapeutic strategies.

Elucidating the role of oncohistone proteins in gene expression mechanisms.

Exploring chromatin structures within unique model organisms, including viruses and nonhuman primates.

Looking Ahead to 2025

As EpiCypher continues to make strides in chromatin and epigenomics technologies, the company aims to broaden its influence in the academic and biotech sectors. The successes of 2024—16 published manuscripts and over 550 product citations—highlight EpiCypher’s growing expertise and leadership.

Looking forward, EpiCypher plans to introduce new sequencing modalities focused on DNA methylation and multiomics, opening doors to new research sectors. "2024 has been a phenomenal year for us, and we are committed to maintaining our momentum," remarked Dr. Cowles, EpiCypher's Chief Business Officer. "With the increasing adoption of our innovative technologies, we foresee 2025 becoming another year of significant growth and discovery."

Stay updated on EpiCypher’s groundbreaking contributions and product offerings to the field of epigenetics by following their progress on social media platforms.

EpiCypher was founded to meet the rising demand for top-quality reagents for studying chromatin regulation and advancing epigenetic drug discovery. With the CUTANA® platform, they offer the most extensive collection of defined designer nucleosomes and comprehensive high-throughput services, positioning themselves at the vanguard of epigenomic research technologies worldwide.